BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Paliperidone palmitate (Erzofri) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Paliperidone palmitate (Erzofri)\, from C
 linicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07927946-9540@assetmemo.bio
DTSTAMP:20261121T005027Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Paliperidone palmitate (Erzofri): Phase 4 readout est. (NCT07927946
 )
DESCRIPTION:Paliperidone palmitate (Erzofri)\, phase 4\, Schizophrenia.\nSt
 udy: Higher-Dose Maintenance With ERZOFRI 351 mg in Adults With Schizophre
 nia\nEstimated primary completion: December 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/paliperidone-palmitate-erzofri#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT07927946
URL:https://assetmemo.bio/drug/paliperidone-palmitate-erzofri#upcoming-even
 ts
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
